Pharming (PHAR) Other Non Operating Income (2019 - 2026)
Pharming's (PHAR) quarterly Other Non Operating Income came in at $7.1 million in Q2 2026, up 463.66% YoY from $1.3 million in Q2 2025, and up 119.93% on a QoQ basis from $3.2 million in Q1 2026.
Pharming (PHAR) Other Non Operating Income (2019 - 2026) Analysis & Trends
Pharming (PHAR) has 8 years of Other Non Operating Income data on file, last reported at $7.1 million in Q2 2026.
- Quarterly Other Non Operating Income rose 463.66% year-over-year to $7.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.1 million (up 294.19% YoY) and the FY2025 annual result came in at $2.2 million, changed N/A from the prior year.
- Other Non Operating Income grew to $7.1 million in Q2 2026, from $3.2 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $9.3 million in Q4 2022 to a low of -$6.8 million in Q4 2024.
- A 5-year average of $945875.0 and a median of $714500.0 in 2024 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income tumbled 144.68% — and 2024, when it jumped 1346.34%.
- Tracing PHAR's Other Non Operating Income over 5 years: stood at $9.3 million in 2022, then slumped by 139.39% to -$3.7 million in 2023, then tumbled by 86.81% to -$6.8 million in 2024, then surged by 68.2% to -$2.2 million in 2025, then surged by 427.16% to $7.1 million in 2026.
- The last three Other Non Operating Income figures came in at $7.1 million (Q2 2026), $3.2 million (Q1 2026), and -$2.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.12 Mn |
| Mar 31, 2026 | 3.24 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Sep 30, 2025 | -119,000.00 |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 604,000.00 |
| Dec 31, 2024 | -6.84 Mn |
| Sep 30, 2024 | 825,000.00 |
| Jun 30, 2024 | 2.94 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | -3.66 Mn |
| Sep 30, 2023 | -1.25 Mn |
| Jun 30, 2023 | -799,000.00 |
| Mar 31, 2023 | 123,000.00 |
| Dec 31, 2022 | 9.30 Mn |
| Sep 30, 2022 | 2.80 Mn |
| Dec 31, 2021 | -8.16 Mn |
| Sep 30, 2021 | 15.03 Mn |
| Dec 31, 2020 | -743,988.87 |
| Sep 30, 2020 | -1.99 Mn |